Viewing Study NCT07085767

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:39 AM
Ignite Modification Date: 2026-01-01 @ 7:22 PM
Study NCT ID: NCT07085767
Status: RECRUITING
Last Update Posted: 2025-12-02
First Post: 2025-07-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Sponsor: Olema Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Locally Advanced Breast Cancer View
None Metastatic Breast Cancer View
None ER Positive Breast Cancer View
None HER2 Negative Breast Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Randomized View
None Multicenter View
None Double-Blind View
None Active-Controlled View
None Phase 3 View
None Palazestrant View
None Complete Estrogen Receptor Antagonist (CERAN) View
None Selective Estrogen Receptor Degrader (SERD) View
None Ribociclib View
None CDK4/6i View
None Letrozole View
None Aromatase inhibitors View
None Antineoplastic agents View